Compare · OBIO vs RLX
OBIO vs RLX
Side-by-side comparison of Orchestra BioMed Holdings Inc. (OBIO) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OBIO and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.39B, about 14.3x OBIO ($237.7M).
- Over the past year, OBIO is up 44.0% and RLX is up 19.0% - OBIO leads by 25.0 points.
- OBIO has been more active in the news (6 items in the past 4 weeks vs 2 for RLX).
- OBIO has more recent analyst coverage (9 ratings vs 2 for RLX).
PerformanceOBIO+43.98%RLX+19.02%
2025-05-02+0.00%2026-05-01
- Company
- Orchestra BioMed Holdings Inc.
- RLX Technology Inc.
- Price
- $3.94-1.00%
- $2.19-1.79%
- Market cap
- $237.7M
- $3.39B
- 1M return
- -9.10%
- +0.00%
- 1Y return
- +43.98%
- +19.02%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2021
- News (4w)
- 6
- 2
- Recent ratings
- 9
- 2
RLX
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest OBIO
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Amendment: SEC Form SCHEDULE 13D/A filed by Orchestra BioMed Holdings Inc.
- Large owner Rtw Investments, Lp exercised 1,250,032 in-the-money shares at a strike of $0.00 and sold $132 worth of shares (32 units at $4.13) (SEC Form 4)
- SEC Form DEFA14A filed by Orchestra BioMed Holdings Inc.
- SEC Form DEF 14A filed by Orchestra BioMed Holdings Inc.
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- SEC Form 4 filed by Sherman Darren
- SEC Form 4 filed by Aiello Joshua
- SEC Form 4 filed by Hochman David P
- Officer Hochman David P bought $42,900 worth of shares (10,000 units at $4.29), increasing direct ownership by 0.93% to 1,086,467 units (SEC Form 4)
Latest RLX
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao
- SEC Form 3 filed by new insider Zhu Zhenjing
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results